Passage BIO Inc
For the period ended Dec 31, 2024. Filed Mar 4, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 4, 2025
PASG$3.43-13.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
(in thousands, except share data)
| | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
| · · Common stock · · Additional · · · Accumulated other · · · Accumulated · · · | ||||||||||||||||
| (in thousands, except share data) · Shares · · Amount · · paid‑in capital · · · comprehensive income (loss) · · deficit · · Total | ||||||||||||||||
| Balance at January 1, 2023 | 54,614,690 | | $5 | $694,733 | | $(966) | | $(492,406) | | $201,366 | ||||||
| Exercise of stock options and vesting of restricted stock units | | 141,534 | | | — | | — | | | — | | | — | | | — |
| Issuance of shares in connection with employee stock purchase plan | | 187,906 | | | — | | 135 | | | — | | | — | | | 135 |
| Unrealized gain (loss) on marketable securities | | — | | | — | — | | | 923 | | | — | | | 923 | |
| Share‑based compensation expense | — | | | — | | 10,921 | | | — | | | — | | | 10,921 | |
| Net loss | — | | | — | | — | | | — | | | (102,062) | | | (102,062) | |
| Balance at December 31, 2023 | 54,944,130 | | $5 | $705,789 | | $(43) | | $(594,468) | | $111,283 | ||||||
| | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | | | | | | | | |
| · · Common stock · · Additional · · · Accumulated other · · · Accumulated · · · | ||||||||||||||||
| (in thousands, except share data) · Shares · Amount · paid‑in capital · · · comprehensive income (loss) · · deficit · · Total | ||||||||||||||||
| Balance at January 1, 2024 | 54,944,130 | | $5 | $705,789 | | $(43) | | $(594,468) | | $111,283 | ||||||
| Issuance of common stock under the ATM Facility, net of offering costs | | 6,000,000 | | | 1 | | 8,741 | | | — | | | — | | | 8,742 |
| Exercise of stock options and vesting of restricted stock units | 912,924 | | — | 35 | | — | | — | | 35 | ||||||
| Issuance of shares in connection with employee stock purchase plan | | 204,720 | | | — | | 97 | | | — | | | — | | | 97 |
| Unrealized gain (loss) on marketable securities | — | | — | — | | 51 | | — | | 51 | ||||||
| Share‑based compensation expense | — | | — | 5,820 | | — | | — | | 5,820 | ||||||
| Net loss | — | | — | — | | — | | (64,767) | | (64,767) | ||||||
| Balance at December 31, 2024 | 62,061,774 | | $6 | $720,482 | | $8 | | $(659,235) | | $61,261 | ||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.